Gene and Protein Information
Species	TM	AA	Chromosomal Location	Gene Symbol	Gene Name	Reference
Human	1	293	17p11.2	TNFRSF13B	TNF receptor superfamily member 13B
Mouse	1	249	11 B2	Tnfrsf13b	tumor necrosis factor receptor superfamily, member 13b
Rat	-	-		Tnfrsf13b	TNF receptor superfamily member 13B

Previous and Unofficial Names

CD267 | tumor necrosis factor receptor superfamily, member 13B | Transmembrane activator and CAML interactor | tumor necrosis factor receptor superfamily member 13B | tumor necrosis factor receptor superfamily | tumor necrosis factor receptor superfamily, member 13b

Database Links
Alphafold	O14836 (Hs), Q9ET35 (Mm)
Ensembl Gene	ENSG00000240505 (Hs), ENSMUSG00000010142 (Mm), ENSRNOG00000002304 (Rn)
Entrez Gene	23495 (Hs), 57916 (Mm), 691719 (Rn)
Human Protein Atlas	ENSG00000240505 (Hs)
KEGG Gene	hsa:23495 (Hs), mmu:57916 (Mm), rno:691719 (Rn)
OMIM	604907 (Hs)
Pharos	O14836 (Hs)
UniProtKB	O14836 (Hs), Q9ET35 (Mm)
Wikipedia	TNFRSF13B (Hs)

Natural/Endogenous Ligands
APRIL {Sp: Human}
BAFF {Sp: Human}

Adaptor proteins (Human)

TRAF2, TRAF5, TRAF6

Other Binding Ligands
Key to terms and symbols		Click column headers to sort
Ligand Sp. Action Value Parameter Reference APRIL {Sp: Human} N/A - - - ⤷ BAFF {Sp: Human} Hs - - - ⤷

Immunopharmacology Comments

TACI is a lymphocyte-specific TNF superfamily receptor expressed on B cells. Endogenous ligands include APRIL, BAFF and CAML. Defects in the function of TACI can underlie immunodeficiencies and autoimmune diseases. TACI ligands are molecular targets of approved and investigational biologics that are intended to treat B cell-mediated immune system defects

Immuno Process Associations

Immuno Process:  B cell (activation)

Immuno Process:  Immune regulation

Immuno Process:  Immune system development

Immuno Process:  Cytokine production & signalling

Immuno Process:  Cellular signalling

Immuno Process:  T cell (activation)

Clinically-Relevant Mutations and Pathophysiology

Disease:  Common variable immunodeficiency Description: CVID is a group of genetically heterogeneous primary immunodeficiencies. Whilst a small number of cases can be linked to deficiency in a single gene (see the OMIM links as examples), the cause is likely to be polygenic in the majority of cases. Symptoms vary between patients, but CVID is generally characterised by a failure to produce antibodies (hypogammaglobulinemia) and therefore susceptibility to recurrent infections and inflammation (including autoimmunity). Disease Ontology: DOID:12177 OMIM: 613495, 607594, 606453, 240500, 613493 Orphanet: ORPHA1572 Role:  Heterozygous, homozygous, or compound heterozygous mutations in the TNFRSF13B gene have been identified as causing common variable immunodeficiency type 2 (CVID2). Comments:  See OMIM: 240500 References:  1-2